Haisco Pharmaceutical Group Co. Ltd. has disclosed quinazolinone derivatives acting as poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors reported to be useful for the treatment of cancer, atopic dermatitis and autoimmune disease.

Nimbus Wadjet Inc. has disclosed compounds reported to be useful for the treatment of cancer.

Incyte Corp. has divulged CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Researchers at Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified aromatic amide derivatives acting as kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Chengdu Chipscreen Pharmaceutical Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Samjin Pharmaceutical Co. Ltd. has disclosed nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors reported to be useful for the treatment of cancer.

Insilico Medicine Ltd. has described protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Ryvu Therapeutics SA has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Tigatx Inc. has been awarded up to $33.5 million in funding by the Advanced Research Projects Agency for Health and a 2-year $2 million Direct to Phase II Small Business Innovation Research grant from the National Cancer Institute.

Anticancer Bioscience Ltd. has identified compounds potentially useful for the treatment of cancer.